Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Expert Opinion on Investigational Drugs|February 10, 2023
Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targetsJoshua W Morse, Margarita Rios, John Ye, et al.
American Journal of Clinical Pathology|March 8, 2023
T-Cell Prolymphocytic Leukemia With t(X;14)(q28;q11.2): A Clinicopathologic Study of 15 CasesZhihong Hu, L Jeffrey Medeiros, Mina Xu, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|June 13, 2025
Hepatic involvement in light chain amyloidosis: analysis of 130 patients and predictors of hepatic response and survivalMatthew J Rees, Nadia Toumeh, Angela Dispenzieri, et al.
British Journal of Haematology|May 10, 2026
Predictors of renal response in AL amyloidosis following anti-plasma cell therapy: The impact of baseline serum free light chain levels and light chain isotypeMatthew J Rees, Binoy Yohannan, Susan Geyer, et al.
Haematologica|May 22, 2025
Clonal plasma cell features in light-chain amyloidosis are associated with depth and timing of cardiac response independent of hematologic responseMatthew J Rees, Susan Geyer, Binoy Yohannan, et al.
Blood Neoplasia|June 2, 2025
Improved survival with daratumumab-CyBorD compared with CyBorD as frontline therapy for AL amyloidosisBinoy Yohannan, Matthew Rees, Morie A Gertz, et al.
JCI Insight|March 22, 2019
Human endotrophin as a driver of malignant tumor growthDawei Bu, Clair Crewe, Christine M Kusminski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2025
New Validated Staging System for Light Chain (AL) Amyloidosis With Stage IIIC Defining Ultra-Poor Risk: AL International Staging SystemJahanzaib Khwaja, Amy A Kirkwood, Paolo Milani, et al.
Blood Cancer Journal|June 23, 2026
Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myelomaBinoy Yohannan, Benjamin W Langworthy, Lindsey E Turner, et al.
Pageof 5